← FDA DRUG APPROVALS

FDA ANDA · ANDA065444

CEPHALEXIN

Sponsor: HIKMA PHARMS

APPLICATION
ANDA065444
TYPE
ANDA
ORIGINAL APPROVAL
2009-08-28
LATEST ACTION
2009-08-28
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Discontinued

Products

CEPHALEXINDiscontinued
CEPHALEXIN EQ 250MG BASE/5ML · FOR SUSPENSION · ORAL
CEPHALEXINDiscontinued
CEPHALEXIN EQ 125MG BASE/5ML · FOR SUSPENSION · ORAL

Approval history

2009-08-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →